



August 24, 2016

## **MediWound's NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016**

### **Multiple oral and poster presentations highlight NexoBrid's and EscharEx' innovative, effective and fast enzymatic debridement of severe burns and chronic wounds**

YAVNE, Israel, Aug. 24, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid<sup>®</sup> and EscharEx<sup>®</sup> will be featured in multiple oral and poster presentations at the 18<sup>th</sup> Congress of the International Society for Burn Injuries (ISBI) taking place August 29 - September 1, 2016 in Miami, Florida. The presentation abstracts will be available online at [www.isbi2016.com](http://www.isbi2016.com).

"We are delighted to once again have NexoBrid featured so prominently at this year's ISBI, one of the world's premier clinical meetings focused on the treatment and prevention of burns. The ISBI brings together the entire team of clinical professionals involved in caring for patients with severe burns in normal and mass casualties conditions on national and international levels," stated Gal Cohen, President and Chief Executive Officer of MediWound.

"The presentations at ISBI highlight not only the success of NexoBrid in routine clinical use, but also in real life emergency situations such as the 2015 Romanian nightclub fire that resulted in a burn mass casualty incident, which is one of the featured oral presentations at the Congress," added Mr. Cohen. "ISBI's mission this year is to further elevate the standards-of-care in emerging countries where there are high burn incidence rates and more limited surgical capacity. We share their goals and look forward to the opportunity to communicate with leading burn specialists from Latin America, Asia-Pacific and other international regions in order to expand NexoBrid access to additional international markets where an effective non-surgical eschar removal agent can further improve burn care management and become the new standard-of-care for severe burns."

The following abstracts regarding NexoBrid have been accepted for presentation by the ISBI organizing committee:

Paper Title:	<b>"A Medical Training Program for the Introduction of NexoBrid Enzymatic Debridement to the Burn Community"</b>
Date/Time:	August 29th from 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall
Paper Title:	<b>"Low Exposure Levels of Respirable Particles during the Preparation of NexoBrid<sup>®</sup> Bromelain Powder"</b>
Date/Time:	August 29th from 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall
Paper Title:	<b>"2015 Bucharest Night Club Fire"</b>
Date/Time:	August 29th from 1:30 p.m. - 3:00 p.m.
Location:	Brickell
Paper Title:	<b>"Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement"</b>
Date/Time:	August 29 <sup>th</sup> from 3:30 p.m. - 5:00 p.m.
Location:	Flagler
Paper Title:	<b>"The Use of Rapid Enzymatic Debridement in the 2015 Romanian Burn Mass Casualty Incident: Groundbreaking Experience"</b>
Date/Time:	August 29th from 3:30 p.m. - 5:00 p.m.
Location:	Tuttle
Paper Title:	<b>"Rapid Enzymatic Debridement of Chronic Wounds: Results of a Multicenter Phase II Trial"</b>
Date/Time:	August 30th from 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall

Paper Title:	<b>"Early Debridement of Sulfur Mustard Contaminated Skin by NexoBrid: Results of a Concept Validation Pig Model Study"</b>
Date/Time:	August 30th from 3:30 p.m. - 5:00 p.m.
Location:	Jasmine
Paper Title:	<b>"New Experience with NexoBrid in Milan Burn Centre: Pros and Cons"</b>
Date/Time:	August 30th at 3:30 p.m. - 5:00 p.m.
Location:	Brickell
Paper Title:	<b>"Acute Healing and Early Scarring after Tissue Preserving Enzymatic Debridement of 13 Severely Burned Faces Compared to Traditional Surgical Debridement"</b>
Date/Time:	August 30th from 3:30 p.m. - 5:00 p.m.
Location:	Monroe
Paper Title:	<b>"Introduction of NexoBrid for Wound Management: Lessons Learned after the First 25 Patients (1 year)"</b>
Date/Time:	August 30th from 3:30 p.m. - 5:00 p.m.
Location:	Monroe
Paper Title:	<b>"The Role of Rapid Enzymatic Escharotomy and Escharectomy in Burn Mass Casualty Incidents"</b>
Date/Time:	August 31st at 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall
Paper Title:	<b>"Use of Enzymatic Debridement in Electrical Burn Injuries: A Case Report"</b>
Date/Time:	August 31st at 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall
Paper Title:	<b>"In Vivo Analysis of NexoBrid Enzymatic Debridement of Full Thickness Burns and Negative Pressure Wound Therapy"</b>
Date/Time:	August 31st at 12:30 p.m. - 1:30 p.m.
Location:	Exhibit Hall
Paper Title:	<b>"The Treatment of Deep Partial Thickness Hand Burns after Enzymatic Debridement with NexoBrid: A Series of Case Reports"</b>
Date/Time:	September 1st at 10:30 a.m. - 12:00 p.m.
Location:	Flagler

## About the ISBI

The International Society for Burn Injuries (ISBI) had its beginnings at the First International Congress on Research in Burns in Bethesda, Maryland in September 1960. Since the ISBI was founded, the total medical care of burn patients has improved considerably. This is not only because medical science has improved but also because there is also a better understanding of the need for a team of professionals of different specialties such as surgeons, anesthesiologists, bacteriologists, critical care physicians, nurses, dietitians, physiotherapists and others. Each and every one of these specialists plays a very important role. One of the main purposes and aims of the ISBI is to disseminate knowledge and to stimulate prevention in the field of burns.

## About NexoBrid

NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe, Israel and Argentina. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or "debridement" is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

## About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid<sup>®</sup>, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe, Israel and Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue.

MediWound's second innovative product, EscharEx<sup>®</sup>, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx contains the same proteolytic enzyme technology as NexoBrid, and benefits from the wealth of existing development data on NexoBrid. In two Phase 2 studies, EscharEx demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.

For more information, please visit [www.mediwound.com](http://www.mediwound.com).

## Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2015 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts:  
Sharon Malka  
Chief Financial and Operations Officer  
MediWound  
[ir@mediwound.co.il](mailto:ir@mediwound.co.il)

Anne Marie Fields  
Senior Vice President  
LHA  
212-838-3777  
[afields@lhai.com](mailto:afields@lhai.com)

 Primary Logo

Source: MediWound Ltd.

News Provided by Acquire Media